Melva Gutierrez-Angulo

Dr. Melva Gutierrez-Angulo

University of Guadalajara, Guadalajara, Jalisco, Mexico
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MRMauro Rossi
Mauro Rossi
EPEdenir Palmero
Edenir Palmero
FLFrancisco López-Kostner
Francisco López-Kostner
CSCarlos Sarroca
Carlos Sarroca
CVCarlos Vaccaro
Carlos Vaccaro
MDMev Dominguez-Valentin
Mev Dominguez-Valentin
Genetic counselling and testing for Lynch syndrome (LS) have recently been introduced in several Latin America countries. We aimed to characterize the clinical, molecular and mismatch repair (MMR) variants spectrum of patients with suspected LS in Latin America. Eleven LS hereditary cancer registries and 34 published LS databases were used to identify unrelated families that fulfilled the Amsterdam II (AMSII) criteria and/or the Bethesda guidelines or suggestive of a dominant colorectal (CRC) inheritance syndrome. We performed a thorough investigation of 15 countries and identified 6 countries where germline genetic testing for LS is available and 3 countries where tumor testing is used in the LS diagnosis. The spectrum of pathogenic MMR variants included MLH1 up to 54%, MSH2 up to 43%, MSH6 up to 10%, PMS2 up to 3% and EPCAM up to 0.8%. The Latin America MMR spectrum is broad with a total of 220 different variants which 80% were private and 20% were recurrent. Frequent regions included exons 11 of MLH1 (15%), exon 3 and 7 of MSH2 (17 and 15%, respectively), exon 4 of MSH6 (65%), exons 11 and 13 of PMS2 (31% and 23%, respectively). Sixteen international founder variants in MLH1, MSH2 and MSH6 were identified and 41 (19%) variants have not previously been reported, thus representing novel genetic variants in the MMR genes. The AMSII criteria was the most used clinical criteria to identify pathogenic MMR carriers although microsatellite instability, immunohistochemistry and family history are still the primary methods in several countries where no genetic testing for LS is available yet. The Latin America LS pathogenic MMR variants spectrum included new variants, frequently altered genetic regions and potential founder effects, emphasizing the relevance implementing Lynch syndrome genetic testing and counseling in all of Latin America countries.

1 May 2022 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
FMFernando Martínez-Esquivias
Fernando Martínez-Esquivias
Melva Gutierrez-AnguloMelva Gutierrez-Angulo
Melva Gutierrez-Angulo
Alejandro Perez-LariosAlejandro Perez-Larios
Alejandro Perez-Larios
JSJorge Alberto Sánchez-Burgos
Jorge Alberto Sánchez-Burgos
Julieta Sarai BecerraJulieta Sarai Becerra
Julieta Sarai Becerra
JGJuan Manuel Guzman-Flores
Juan Manuel Guzman-Flores
Health systems worldwide consider cancer a disease that causes the highest number of deaths per year. The low efficacy of current cancer therapies has led other areas of science to search for new alternatives, including nanomaterial sciences. Selenium nanoparticles have anticancer activity, as revealed by in vitro tests performed on prostate, breast, cervical, lung, colorectal, and liver cancer cell lines. Studies attribute anticancer activity to the anti-metastatic effect due to the inhibition of migration and invasion processes. The antiproliferative effect is the low expression of molecules such as cyclin D1, cyclin E, and CDK2. In addition to the activation of cell apoptosis by caspase-dependent mechanisms, there is a low expression of anti-apoptotic proteins such as Bcl-2 and a high expression of the apoptotic proteins like Bax and Bad. Other studies attribute anticancer activity to the activation of cell necroptosis, where molecules such as TNF and IRF1 participate. The pharmacological potential of selenium nanoparticles depends primarily on the administered dose, particle size, and chemical composition. Furthermore, several studies have shown that the administration of these nanoparticles is safe due to their low toxicity in non-cancerous cells. In this review, the most relevant antecedents on the anticancer potential of selenium nanoparticles in prostate, breast, cervical, lung, liver, and colorectal cancer cell lines are discussed.

8 August 2023 in Frontiers in Genetics
Verified
Journal Article
Open access
Melva Gutierrez-AnguloMelva Gutierrez-Angulo
Melva Gutierrez-Angulo
Maria de la Luz Ayala-MadrigalMaria de la Luz Ayala-Madrigal
Maria de la Luz Ayala-Madrigal
JMJose Miguel Moreno-Ortiz
Jose Miguel Moreno-Ortiz
JPJorge Peregrina-Sandoval
Jorge Peregrina-Sandoval
FGFernando Daniel Garcia-Ayala
Fernando Daniel Garcia-Ayala
Colorectal cancer is a complex disease resulting from the interaction of genetics, epigenetics, and environmental factors. DNA methylation is frequently found in tumor suppressor genes to promote cancer development. Several factors are associated with changes in the DNA methylation pattern, and recently, the gastrointestinal microbiota could be associated with this epigenetic change. The predominant phyla in gut microbiota are Firmicutes and Bacteroidetes; however, an enrichment of Bacteroides fragilis, Fusobacterium nucleatum, and Streptococcus bovis, among others, has been reported in colorectal cancer, although the composition could be influenced by several factors, including diet, age, sex, and cancer stage. Fusobacterium nucleatum, a gram-negative anaerobic bacillus, is mainly associated with colorectal cancer patients positive for the CpG island methylator phenotype, although hypermethylation in genes such as MLH1, CDKN2A, MTSS1, RBM38, PKD1, PTPRT, and EYA4 has also been described. Moreover, Hungatella hathewayi, a gram-positive, rod-shaped bacterium, is related to hypermethylation in SOX11, THBD, SFRP2, GATA5, ESR1, EYA4, CDX2, and APC genes. The underlying epigenetic mechanism is unclear, although it could be implicated in the regulation of DNA methyltransferases, enzymes that catalyze the transfer of a methyl group on cytosine of CpG sites. Since DNA methylation is a reversible event, changes in gut microbiota could modulate the gene expression through DNA methylation and improve the colorectal cancer prognosis.

3 October 2008 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
TFThomas V. Fernandez
Thomas V. Fernandez
IGI.J. García‐González
I.J. García‐González
CMChristopher E. Mason
Christopher E. Mason
GHG. Hernández‐Zaragoza
G. Hernández‐Zaragoza
VLV.C. Ledezma‐Rodríguez
V.C. Ledezma‐Rodríguez
NDNory O. Dávalos
Nory O. Dávalos

21 January 2011 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
MPMiriam Partida-Pérez
Miriam Partida-Pérez
MAMaría de la Luz Ayala-Madrigal
María de la Luz Ayala-Madrigal
JPJorge Peregrina-Sandoval
Jorge Peregrina-Sandoval
NMNelly Margarita Macías-Gómez
Nelly Margarita Macías-Gómez
JMJosé Moreno-Ortiz
José Moreno-Ortiz
Melva Gutierrez-AnguloMelva Gutierrez-Angulo
Melva Gutierrez-Angulo
Leptin and adiponectin are cytokines produced by adipose tissue with opposite effects on tumor growth: the former stimulate whereas the latter inhibit it. The objective was to analyze the association of LEP A19G and ADIPOQ+45 T/G and +276 G/T polymor

5 December 2018 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
CVCarlos Alberto Vaccaro
Carlos Alberto Vaccaro
FLFrancisco López‐Kostner
Francisco López‐Kostner
DADella Valle Adriana
Della Valle Adriana
EPEdenir Palmero
Edenir Palmero
BRBenedito Mauro Rossi
Benedito Mauro Rossi
IGin collaboration with GETH
in collaboration with GETH
Colorectal cancer (CRC) is one of the most common cancers in Latin America and the Caribbean, with the highest rates reported for Uruguay, Brazil and Argentina. We provide a global snapshot of the CRC patterns, how screening is performed, and compared/contrasted to the genetic profile of Lynch syndrome (LS) in the region. From the literature, we find that only nine (20%) of the Latin America and the Caribbean countries have developed guidelines for early detection of CRC, and also with a low adherence. We describe a genetic profile of LS, including a total of 2,685 suspected families, where confirmed LS ranged from 8% in Uruguay and Argentina to 60% in Peru. Among confirmed LS, path_MLH1 variants were most commonly identified in Peru (82%), Mexico (80%), Chile (60%), and path_MSH2/EPCAM variants were most frequently identified in Colombia (80%) and Argentina (47%). Path_MSH6 and path_PMS2 variants were less common, but they showed important presence in Brazil (15%) and Chile (10%), respectively. Important differences exist at identifying LS families in Latin American countries, where the spectrum of path_MLH1 and path_MSH2 variants are those most frequently identified. Our findings have an impact on the evaluation of the patients and their relatives at risk for LS, derived from the gene affected. Although the awareness of hereditary cancer and genetic testing has improved in the last decade, it is remains deficient, with 39%–80% of the families not being identified for LS among those who actually met both the clinical criteria for LS and showed MMR deficiency.